Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TXK | P42681 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2654968 | 1.00 | GCK (0.37) | GCKKCNH2SMN1; SMN2TXKJAK3 | |
| SCHEMBL2654256 | 0.87 | GCK (0.49) | GCKSMN1; SMN2 | |
| SCHEMBL2654261 | 0.87 | GCK (0.49) | GCKSMN1; SMN2 | |
| SCHEMBL2655762 | 0.84 | GCK (0.41) | GCKKCNH2 | |
| SCHEMBL2655764 | 0.84 | GCK (0.41) | GCKKCNH2 | |
| SCHEMBL2653319 | 0.82 | GCK (0.41) | GCKKCNH2SMN1; SMN2 | |
| SCHEMBL2653324 | 0.82 | GCK (0.41) | GCKKCNH2SMN1; SMN2 | |
| SCHEMBL2653459 | 0.79 | GCK (0.38) | GCKKCNH2SMN1; SMN2 | |
| SCHEMBL2653456 | 0.79 | GCK (0.38) | GCKKCNH2SMN1; SMN2 | |
| SCHEMBL2654590 | 0.78 | GCK (0.40) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262196-B2 | Tri(cyclo) substituted amide glucokinase activator compounds | PROSIDION LIMITED (GB) | 2007-08-28 | — | — | US | claimed |
| EP-1594863-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | claimed |
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | OSI PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004072066-A1 | TRI(CYCLO) SUBSTITUTED AMIDE GLUCOKINASE ACTIVATOR COMPOUNDS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | claimed |
| US-7262196-B2 | Tri(cyclo) substituted amide glucokinase activator compounds | PROSIDION LIMITED (GB) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186290-A1 | Tri(cyclo) substituted amide glucokinase activator compounds | GCKR, GCK, GALK1 | GCK 2/4885KCNH2 1946/4885SMN1; SMN2 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.